CY1116316T1 - METHODS AND COMPOSITIONS INCLUDING EXTRAORDINARY FORMS - Google Patents

METHODS AND COMPOSITIONS INCLUDING EXTRAORDINARY FORMS

Info

Publication number
CY1116316T1
CY1116316T1 CY20151100465T CY151100465T CY1116316T1 CY 1116316 T1 CY1116316 T1 CY 1116316T1 CY 20151100465 T CY20151100465 T CY 20151100465T CY 151100465 T CY151100465 T CY 151100465T CY 1116316 T1 CY1116316 T1 CY 1116316T1
Authority
CY
Cyprus
Prior art keywords
methods
present
compositions including
variety
antibodies
Prior art date
Application number
CY20151100465T
Other languages
Greek (el)
Inventor
Claude Yves Nicolau
Ruth Greferath
David Hickman
Original Assignee
Ac Immune Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/783,975 external-priority patent/US20040242845A1/en
Priority claimed from US10/958,211 external-priority patent/US8663650B2/en
Application filed by Ac Immune Sa filed Critical Ac Immune Sa
Publication of CY1116316T1 publication Critical patent/CY1116316T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes

Abstract

Η παρούσα εφεύρεση περιλαμβάνει νέες συνθέσεις και μεθόδους προκλήσεως υψηλών ανοσολογικών αποκρίσεων, μεγάλης ειδικότητας που αποδίδουν αντισώματα ευαίσθητα από άποψη διαμορφώσεως. Αυτά τα αντισώματα αναγνωρίζουν συγκεκριμένους επιτόπους επί μίας μεγάλης ποικιλίας αντιγόνων που περιλαμβάνουν, αλλά όχι περιοριστικά, αμυλοειδή πρωτεΐνη, πρωτεΐνη πρίον, γλυκοπρωτεΐνη Ρ170· Οι νέες συνθέσεις της εφευρέσεως περιλαμβάνουν υπερμοριακά αντιγονικά μορφώματα που γενικά περιλαμβάνουν μία πεπτιδική αλληλουχία, ομοιοπολικά προσδεδεμένη σε πεγκυλιωμένη λυσίνη καταλήγοντας σε τροποποιημένη και ενισχυμένη πεπτιδική παρουσίαση. Η μοναδική μεθοδολογία τροποποιήσεως της παρούσας εφευρέσεως είναι εφαρμόσιμη σε μία ποικιλία πεπτιδίων και μπορεί τελικά να χρησιμοποιηθεί σε θεραπευτικές συστάσεις και εμβόλια για νόσους και διαταραχές όπως η νόσος Alzheimer.The present invention encompasses novel compositions and methods of inducing high specific immune responses of high specificity that confer modulation-sensitive antibodies. These antibodies recognize specific epitopes on a wide variety of antigens including, but not limited to, amyloid protein, prion protein, glycoprotein P170; modified and enhanced peptide presentation. The unique modification methodology of the present invention is applicable to a variety of peptides and may eventually be used in therapeutic recommendations and vaccines for diseases and disorders such as Alzheimer's disease.

CY20151100465T 2004-02-20 2015-05-25 METHODS AND COMPOSITIONS INCLUDING EXTRAORDINARY FORMS CY1116316T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/783,975 US20040242845A1 (en) 2003-02-21 2004-02-20 Methods and compositions comprising supramolecular antigenic constructs and antibodies elicited against them
US10/958,211 US8663650B2 (en) 2003-02-21 2004-10-04 Methods and compositions comprising supramolecular constructs
EP12153152.9A EP2465533B1 (en) 2004-02-20 2005-02-22 Methods and compositions comprising supramolecular constructs

Publications (1)

Publication Number Publication Date
CY1116316T1 true CY1116316T1 (en) 2017-02-08

Family

ID=46395388

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100465T CY1116316T1 (en) 2004-02-20 2015-05-25 METHODS AND COMPOSITIONS INCLUDING EXTRAORDINARY FORMS

Country Status (11)

Country Link
JP (1) JP4934433B2 (en)
KR (1) KR101277004B1 (en)
CY (1) CY1116316T1 (en)
DK (1) DK2465533T3 (en)
ES (2) ES2539262T3 (en)
HK (2) HK1130698A1 (en)
HR (1) HRP20150612T1 (en)
HU (1) HUE025186T2 (en)
PT (1) PT2465533E (en)
RS (1) RS54074B1 (en)
SI (1) SI2465533T1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2408807T1 (en) * 2009-03-18 2021-11-30 Ac Immune Sa Method for therapeutic use
EP2632434A1 (en) * 2010-10-26 2013-09-04 AC Immune S.A. Liposome-based construct comprising a peptide modified through hydrophobic moieties

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6187335B1 (en) * 1997-12-31 2001-02-13 Orasomal Technologies, Inc. Polymerizable fatty acids, phospholipids and polymerized liposomes therefrom
AU2600499A (en) * 1998-02-13 1999-08-30 Arch Development Corporation Methods and compositions comprising the use of blocked b-amyloid peptide
CA2393638C (en) * 1999-12-22 2009-10-20 Shearwater Corporation Method for the preparation of 1-benzotriazolyl carbonate esters of poly(ethylene glycol)

Also Published As

Publication number Publication date
HUE025186T2 (en) 2016-02-29
HK1130698A1 (en) 2010-01-08
SI2465533T1 (en) 2015-07-31
HRP20150612T1 (en) 2015-07-03
PT2465533E (en) 2015-06-24
HK1172260A1 (en) 2013-04-19
JP2007527870A (en) 2007-10-04
ES2385226T3 (en) 2012-07-19
ES2539262T3 (en) 2015-06-29
KR101277004B1 (en) 2013-06-24
RS54074B1 (en) 2015-10-30
KR20120097546A (en) 2012-09-04
ES2385226T9 (en) 2013-10-10
JP4934433B2 (en) 2012-05-16
DK2465533T3 (en) 2015-04-20

Similar Documents

Publication Publication Date Title
ATE552848T1 (en) METHODS AND COMPOSITIONS USING SUPRAMOLECULAR CONSTRUCTS
CY1115014T1 (en) Monoclonal Antibodies Specific For Ab1-42 With Therapeutic Properties
CY1119792T1 (en) Protein-based therapy and diagnosis of TAU-mediated pathology in Alzheimer's disease
ATE369380T1 (en) VACCINE FOR PREVENTING AND TREATING ALZHEIMER'S DEMENTIA AND AMYLOID-RELATED DISEASES
CY1118037T1 (en) ANTIBODIES AGAINST AVETA AND THEIR USE
EA200601671A1 (en) IDENTIFICATION OF OWN AND ALIEN ANTIGENES INVOLVED IN AUTOIMMUNE DISEASES
NO20022531L (en) Vaccine for the prevention and treatment of Alzheimer's and amyloid-related diseases
ATE510851T1 (en) PEPTIDE-BASED IMMUNIZATION THERAPY FOR THE TREATMENT OF ATHEROSCLERosis
CY1117643T1 (en) NANCY VACCINE COMPOSITIONS INCLUDING ANTIGON COMBINATION
AT500379B1 (en) TAU PROTEINS
CY1110634T1 (en) Methods for the Prevention and Treatment of Alzheimer's Disease (AD)
EA200700136A1 (en) ANTI-CD154-ANTIBODIES
CY1115316T1 (en) Peptides for Beta-Amyloidosis Therapeutic Treatment
AR107290A1 (en) PEPTIDE ANTIBODIES b AMILOID ANTI-N3pGlu AND USES OF THE SAME
AU2003270643A8 (en) Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence
DK1362109T3 (en) Recombinant oligomeric protein complexes with enhanced immunogenic potential
EP2403871A4 (en) Antibodies and epitopes specific to misfolded prion protein
CY1116316T1 (en) METHODS AND COMPOSITIONS INCLUDING EXTRAORDINARY FORMS
HK1088909A1 (en) Peptide-based immunization therapy for treatment of atherosclerosis
ATE450272T1 (en) BORDETELLA RECOMBINANT ADENYLATE CYCLASE TOXIN INDUCES T CELL RESPONSES AGAINST TUMORAL ANTIGENS
CY1105947T1 (en) MYCOPLASMA HYOPNEUMONIAE MHP3 GENE NUCLEIC ACIDS AND PROTEINS AND USES THEREOF
DK1019085T3 (en) Non-anaphylactic forms of allergens and their use
MX2022011199A (en) Cyclic peptides.
UA97631C2 (en) Therapeutic vaccine